CURRICULUM DR.SSA SIMONA BURSI

Транскрипт

1 INFORMAZIONI PERSONALI CURRICULUM DR.SSA SIMONA BURSI NOME: BURSI SIMONA DATA DI NASCITA: 15/07/1980 QUALIFICA: MEDICO INCARICO ATTUALE: DIRIGENTE MEDICO, U.O ONCOLOGIA MEDICA, AZ USL 6 LIVORNO PRESIDIO DI LIVORNO NUM. TEL. UFFICIO: FAX UFFICIO: ISTITUZIONALE: [email protected] TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE TITOLO DI STUDIO: LAUREA IN MEDICINA E CHIRURGIA (2004) ALTRI TITOLI DI STUDIO E PROFESSIONALI: SPECIALIZZAZIONE IN ONCOLOGIA (2009) ESPERIENZE PROFESSIONALI (INCARICHI RICOPERTI): DALL APRILE AL DICEMBRE 2009 È STATA TITOLARE DI UN CONTRATTO DELLA SOCIETÀ ARCO FONDAZIONE RICECHE E CURE IN ONCOLOGIA O.N.L.U.S. PER LA REALIZZAZIONE DI UN PROGETTO DAL TITOLO VALUTAZIONE RETROSPETTIVA DELLO STATO MUTAZIONALE DI K- RAS E DELLA DETERMINAZIONE IMMUNOISTOCHIMICA DI P-AKT, DI PTEN ED IGF-1R QUALI FATTORI PREDITTIVI DI RISPOSTA AL TRATTAMENTO CON FARMACI TARGET-ORIENTED. DAL 16/05/2010 RICOPRE L'INCARICO DI DIRIGENTE MEDICO A TEMPO INDETERMINATO PRESSO LA U.O. ONCOLOGIA MEDICA, AZ USL & LIVORNO PRESIDIO DI LIVORNO. ATTUALMENTE SI OCCUPA PREVALENTEMENTE DI NEOPLASIE DELL'APPARATO UROLOGICO MASCHILE E DI MELANOMA CAPACITA' LINGUISTICHE: CAPACITÀ DI LETTURA: CAPACITÀ DI SCRITTURA: CAPACITÀ DI ESPRESSIONE ORALE: LINGUA INGLESE CAPACITÀ NELL'USO DELLE TECNOLOGIE:

2 ALTRO Lavori in estenso su riviste internazionali con revisori e recensite P1) First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. G. Masi, L. Marcucci, F. Loupakis, E. Cerri, C. Barbara, S. Bursi, G. Allegrini, I.M. Brunetti, R. Murr, S. Ricci, S. Cupini, M. Andreuccetti and A. Falcone. Ann Oncol, 17: , P2) Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. G. Masi, E. Vasile, F. Loupakis, S. Bursi, S. Ricci, I. Petrini, A. Fontana, G. Allegrini, A. Falcone. Clin Colorectal Cancer, 7: 7-14, P3) A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. L. Fornaro, G. Masi, S. Bursi, F. Loupakis, E. Vasile, A. Antonuzzo, S. Chiara, E. Pfanner, A. Di Paolo, G. Bocci, M. Del Tacca, A. Falcone. Cancer Chemother Pharmacol, 2009 Apr;63(5):965-9 P4) A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first line treatment of metastatic colorectal cancer. E. Vasile, G. Masi, L. Fornaro, S. Cupini, F. Loupakis, S. Bursi, I. Petrini, S. Di Donato, IM Brunetti, S. Ricci, A. Antonuzzo, S. Chiara, D. Amoroso, M. Andreuccetti. A. Falcone. Br J Cancer, 2009 Jun 2; 100(11): P5) Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib and dexamethasone in advanced hormone-refractory prostate cancer. A. Fontana, L. Galli, A. Fioravanti, P. Orlandi, C. Galli, L. Landi, S. Bursi, G. Allegrini, E. Fontana, R. Di Marsico, A. Antonuzzo, M. D Arcangelo, R. Danesi, M. Del Tacca, A. Falcone, G. Bocci. Clin Cancer Res, 2009; 15(15) August 1, 2009 P6) Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. Fontana A. Bocci G., Galli L., D'Arcangelo M., Derosa l., Orlandi A., Fioravanti P., Barletta MT, Landi L., Bursi S., Minuti G., Bona E., Grazzini I., Danesi R., Falcone A. J Am Geriatr Soc 2010 May 58(5):986-8 P7) Consequences of targeted treatments for second-line therapy. De Maio E., C. Tibaldi, A. D'Incecco, S. Bursi, C. Barbara, Cupini S., R. Di Marsico, M. D'Arcangelo, L. Landi, G. Minuti, F. Cappuzzo. Ann Oncol 2010 Oct;21 Suppl 7:vii Lavori in estenso su riviste in lingua italiana P8) Il trattamento con 5-fluorouracile/acido folinico, oxaliplatino e irinotecano (FOLFOXIRI) consente di riportare alla resezione chirurgica le metastasi di pazienti con carcinoma colorettale metastatico inizialmente non resecabili. Treatment by FOLFOXIRI allows surgical resection of colon cancer metastases non previously resectable. S. Bursi, G. Masi, F. Loupakis, S. Cupini, L. Marcucci, I. Brunetti, E. Pfanner, M. Viti, L. Giuliani, F. Filippini, F. Mosca, A. Falcone. Acta Med Labronica, 3: 35-45, 2006.

3 ABSTRACTs A1) Second line chemotherapy after first line folfoxiri in metastatic colorectal cancer (MCRC) patients (PTS). L. Marcucci, S. Cupini, G. Masi, G. Allegrini, E. Cerri, F. Loupakis, S. Bursi, E. Fontana, A. Falcone. Atti VII Congresso Nazionale G.O.N.O., Pisa, Novembre: 51, A2) Irinotecan (I) in associazione a capecitabina (C) seguiti da oxaliplatino (O) + C in pazienti (pz) anziani vulnerabili con carcinoma colorettale metastatico (CCRM): risultati preliminari di uno studio multicentrico di fase II. S. Bursi, E. Cerri, G. Masi, G. Allegrini, S. Cupini, L. Marcucci, F. Loupakis, C. Barbara, S. Ricci, I. Brunetti, R. Murr, M. Andreuccetti, A. Falcone. Atti VII Congresso Nazionale G.O.N.O., Pisa, Novembre: 30, A3) Trattamento chemioterapico metronomico con iritotecano (CPT-11) in pazienti con diagnosi di carcinoma colorettale metastatico: valutazione clinica e farmacodinamica. E. Cerri, G. Bocci, F. Loupakis, L. Marcucci, S. Bursi, A. Fioravanti, P. Orlandi, A. Fontana, G. Masi, M. Andreuccetti, G. Allegrini, R. Danesi, M. Del Tacca, A. Falcone. Atti VII Congresso Nazionale G.O.N.O., Pisa, Novembre: 28, A4) Capecitabine (C) in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.). S. Bursi, G. Masi, A. Antonuzzo, F. Loupakis, C. Barbara, M. Barletta, G. Allegrini, E. Pfanner, R. Murr, A. Falcone. Proceedings 31 st ESMO Congress, Istanbul, Turkey, 29 September 3 October, In: Annals of Oncology 17, Suppl 9, A5) Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.). F. Loupakis, G. Masi, E. Fontana, G. Allegrini, S. Bursi, C. Barbara, E. Cerri, M.T. Barletta, V. Picone, L. Mentuccia, C. Granetto, E. Fea, E. Pfanner, R. Murr, I. Brunetti, M. Andreuccetti, A. Falcone. Proceedings 8 th National Congress of Medical Oncology, Milan, November, In: Ann. Oncol. 17 (Suppl. 11): xi50, A6) Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.). S. Bursi, G. Masi, A. Antonuzzo, E. Cerri, F. Loupakis, C. Barbara, M. Barletta, G. Allegrini, S. Cupini, S. Ricci, I. Brunetti, E. Pfanner, M. Lencioni, R. Murr, I. Petrini, L. Tognarini, M. Andreuccetti, A. Falcone. Proceedings 8 th National Congress of Medical Oncology, Milan, November, In: Ann. Oncol. 17 (Suppl. 11): xi41, A7) Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (IR) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologico Nord-Ovest (GONO). F. Loupakis, G. Masi, S. Bursi, V. Picone, L. Mentuccia, C. Granetto, E. Fea, R. Murr, A. Antonuzzo, A. Falcone. Proceedings 43rd Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, Illinois, 1-5 June, In: JCO 25: 18S, A8) The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.). G. Masi, S. Bursi, F. Loupakis, M. Barletta, G. Baldi, A. Antonuzzo, C. Sonaglio, E. Pfanner, I. Petrini, A. Falcone. Proceedings 43rd Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, Illinois, 1-5 June, In: JCO 25: 18S, 2007.

4 A9) Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(mcrc): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study. A. Falcone, M. Andreuccetti, S. Ricci, C. Orlandini, C. Barbara, W. Evangelista, L. Ciuffreda, E. Cortesi, R. Ferraldeschi, S. Chiara, C. Granetto, F. Loupakis, S. Bursi, G. Allegrini, G. Masi. Proceedings 9 th World Congress on Gastrointestinal Cancer (WCGC), Barcelona, Spain, 28 June- 1 July, In: Ann Oncol 18, A10) Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line folfoxiri followed by r0 surgical resection of metastases. G. Masi, S. Bursi, F. Loupakis, M. Barletta, C. Barbara, E. Vasile, S. Cupini, I. Brunetti, E. Pfanner, S. Di Donato, G. D Auria, L. Fanchini, S. Chiara, C. Granetto, A. Falcone. Proceedings 9 th World Congress on Gastrointestinal Cancer (WCGC), Barcelona, Spain, 28 June- 1 July, In: Ann Oncol 18, A11) First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group. S. Bursi, G. Masi, F. Loupakis, A. Antonuzzo, L. Tognarini, C. Sonaglio, S. Chiara, E. Pfanner, I. Brunetti, I. Petrini, G. Baldi, M. Barletta, G. Allegrini, S. Ricci, A. Falcone. Proceedings 9 th World Congress on Gastrointestinal Cancer (WCGC), Barcelona, Spain, 28 June- 1 July, In: Ann Oncol 18, A12) Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases. G. Masi, S. Bursi, F. Loupakis, C. Barbara, I. Brunetti, R. Ferraldeschi, W. Evangelista, S. Chiara, C. Granetto, A. Falcone. Proceedings 14 th European Cancer Conference (ECCO), Barcelona, Spain, September, In: EJC vol. 5, 4: 242, A13) Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC). S. Cupini, S. Bursi, G. Masi, F.Loupakis, C. Barbara, L. Fornaro, G. Allegrini, R. Di Marsico, M. Andreuccetti, A. Falcone. Proceedings 14 th European Cancer Conference (ECCO), Barcelona, Spain, September, In: EJC vol. 5, 4: 251, A14) Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord- Ovest (G.O.N.O.). S. Bursi, G. Masi, F. Loupakis, A. Antonuzzo, S. Chiara, E. Pfanner, I. Petrini, M.T. Barletta, G.G. Baldi, A. Falcone. Proceedings 14 th European Cancer Conference (ECCO), Barcelona, Spain, September, In: EJC vol. 5, 4: 255, A15) Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report. M.T. Barletta, G. Bocci, F. Loupakis, A. Fioravanti, G. Baldi, P. Orlandi,, G. Allegrini, G. Masi, C. Barbara, M. Andreuccetti, S. Cupini, S. Bursi, R. Danesi, A. Di Paolo, M. Del Tacca, A. Falcone. Proceedings 9 th National Congress of Medical Oncology (AIOM), Palermo, Italy, October, In: Ann Oncol 18 (suppl 11): xi4, A16) Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC). S. Cupini, S. Bursi, G. Masi, F. Loupakis, C. Barbara, M.T. Barletta, G.G. Baldi, E. Vasile, L. Fornaro, I. Petrini, G. Allegrini, A. Antonuzzo, R. Di Marsico, M. Andreuccetti, S. Ricci, A. Falcone. Proceedings 9 th National Congress of Medical

5 Oncology (AIOM), Palermo, Italy, October, In: Ann Oncol 18 (suppl 11): xi6, A17) First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.). S. Bursi, G. Masi, F. Loupakis, A. Antonuzzo, L. Tognarini, C. Sonaglio, S. Chiara, E. Pfanner, I. Brunetti, I. Petrini, G. G. Baldi, M.T. Barletta, L. Fornaro, G. Allegrini, S. Donati, M. Andreuccetti, S. Ricci, A. Falcone. Proceedings 9 th National Congress of Medical Oncology (AIOM), Palermo, Italy, October, In: Ann Oncol 18 (suppl 11): xi6, A18) First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts). G. Masi, F. Loupakis, S. Bursi, C. Barbara, M.T. Barletta, G. Baldi, S. Cupini, I. Brunetti, E. Pfanner, M. Lencioni, S. Di Donato, L. Mentuccia, L. Fanchini, C. Sonaglio, E. Fea, G. Allegrini, A. Falcone. Proceedings 9 th National Congress of Medical Oncology (AIOM), Palermo, Italy, October, In: Ann Oncol 18 (suppl 11): xi21, A19) Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with aggressive b-cell non-hodgkin s lymphoma (NHL). E. Capochiani, S. Cupini, F. Loupakis, E. Vasile, A. Fontana, C. Barbara, S. Bursi, L. Landi, L. Coltelli, V. Safina, M.T. Barletta, G.G. Baldi, N. Giuntini, M. Lo Dico, E. Mazzoni, G. Masi, A. Falcone. Proceedings 9 th National Congress of Medical Oncology (AIOM), Palermo, Italy, October, In: Ann Oncol 18 (suppl 11): xi67, A20) Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation. A. Fontana, G. Bocci, M. D Arcangelo, L. Galli, C. Galli, S. Bursi, L. Landi, A. Antonuzzo, M. Del Tacca, A. Falcone. Proceedings 44 th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago, Illinois, 30 May - 3 June, In: JCO 26, A21) Docetaxel (D) plus Prednisone (P) in combination with metronomic Cyclophosphamide (CTX) and Celecoxib (C) as first line treatment in metastatic hormone refractory prostate cencer (MHRPC): A phase II clinical trial with pharmacodynamic evaluation. A. Fontana, G. Bocci, M. D Arcangelo, L. Galli, S. Bursi, L. Landi, P. Battaglini, S. Caponi, M. Del Tacca, A. Falcone. Proceedings 33 rd ESMO Congress, Stockholm, Sweden, September, In: Ann Oncol 19 (Suppl 8): viii198 viii199, A22) Il trattamento del carcinoma del colon-retto metastatico. Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. G. Masi, E. Vasile, F. Loupakis, S. Bursi, S. Ricci, I. Petrini, A. Fontana, G. Allegrini, A. Falcone. Atti Giornata Regionale AIOM Toscana, Sovigliana, Vinci (Firenze), 25 Settembre, A23) Pegfilgrastim to support chop-r chemotherapy administered every 14 days in patients (PTS) with aggressive B-cell non-hodgkin s lymphoma (NHL). S. Cupini, E. Capochiani, S. Bursi, L. Landi, L. Coltelli, N. Giuntini, M. Lo Dico, E. Mazzoni, G. G. Baldi, M. T. Barletta, L. Fornaro, I. Stasi, A. D Incecco, L. Salvatore, S. Caponi, E. Bona, P. Battaglini, G. Masi, A. Falcone. Proceedings 10 th National Congress of Medical Oncology (AIOM), Verona, Italy, October, In: Ann Oncol 19 (Suppl 9): ix9, A24) Retrospective analysis of concomitant treatment with 3-dimensional conformal radiotherapy and temozolomide in high-grade glioma patients. L. Landi, A. Fontana, C. Galli, L. Galli, S. Bursi, P. Battaglini, S. Caponi, M. D Arcangelo, R. Gagliardi, L. Benvenuti, M. Bosio, S. Capoccia, M. Andreuccetti, A. Falcone. Proceedings 10 th National Congress of Medical Oncology (AIOM), Verona, Italy, October, In: Ann Oncol 19 (Suppl 9): ix40, 2008.

6 A25) Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC). A. Fontana, G. Bocci, M. D Arcangelo, L. Galli, C. Galli, S. Bursi, L. Landi, A. Fioravanti, P. Orlandi, P. Battaglini, S. Caponi, A. Antonuzzo, L. Derosa, G. Minuti, M. Andreuccetti, M. Del Tacca, A. Falcone. Proceedings 10 th National Congress of Medical Oncology (AIOM), Verona, Italy, October, In: Ann Oncol 19 (Suppl 9): ix50, A26) Low-dose metronomic cyclophosphamide (CTX) plus celecoxib (c) and dexamethasone (DEX) in elderly patients (>78 years) with advanced castration resistant prostate cancer (CRPC). A. Fontana, G. Bocci, L. Derosa, L. Galli, C. Galli, S. Bursi, P. Orlandi, S. Caponi, G. Minuti, A. Falcone. ASCO 2009 Genitourinary Cancers Symposium A27) Phase II study of Docetaxel-Prednisone (DP) in combination with metronomic Cyclophosphamide (CTX) and Celecoxib (C) as first line treatment in Castration Resistant Prostate Cancer (CRPC) patients (Pts). A. Fontana, G. Bocci, L. Galli, L. Derosa, G. Minuti, M. D'Arcangelo, D. Santini, L. Landi, S. Bursi, A. Falcone. In: J Clin Oncol 27, 2009 (suppl; abstr e16032). A28) Pegfilgrastim to support R-CHOP q14 chemotherapy in the patients (PTS) with aggressive B-cell Non- Hodgkin s lymphoma (NHL). E. Capochiani, S. Cupini. S. Bursi, L. Landi, L. Coltelli, N. Giuntini, M. Barletta, G.G. Baldi, I. Stasi, A. Falcone. In: Haematologica 2009; 94(s2). A29) Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC). A. Fontana, L. Galli, L. Derosa, G. Minuti, M. D Arcangelo, S. Bursi, L. Landi, G. Bocci, D. Santini, A. Falcone. EJC Vol 7 No 2 September 2009 A30) Rituximab plus pegylated liposomal doxorubicin in combination with cyclophosphamide: a first line therapeutic option for very elderly or unfit patients with aggressive non Hodgkin lymphoma. E. Capochiani, S. Cupini, S. Bursi, S. Caponi, A. Falcone. In: Haematologica 2009; 94(s4). A31) Docetaxel-Prednisone (DP) plus metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC): phase II trial with pharmacodynamic evaluation. A. Fontana, L. Galli, L. Derosa, G. Minuti, M. D Arcangelo, E. Fontana, R. Di Marsico, O. Venditti. S. Galluzzo, L. Landi, S. Bursi, C. Galli, E. Bona, G. Bocci, A. Antonuzzo, A. Falcone. In: Ann Oncol, Volume 20, 2009 Supplement 8 A32) Metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): a phase II clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluation. L. Galli, A. Fontana, L. Derosa, G. Minuti, M. D Arcangelo, E. Fontana, V. Safina, L. Landi, S. Bursi, C. Galli, E. Bona, G. Bocci, A. Antonuzzo, A. Falcone. In: Ann Oncol, Volume 20, 2009 Supplement 8